SCHEMBL771726

SCHEMBL771726

O=C(CCCSC(=S)NC(c1ccccc1)c1ccccc1)N1CCCC2CCCCC21

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TACR1 P25103 7/20 0.41
HSD11B1 P28845 3/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B1 P14061 1/20 0.39
LMNA P02545 1/20 0.39
DUT P33316 1/20 0.39
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 1/20 0.38
CHRM3 P20309 1/20 0.38
ACE P12821 1/20 0.37
ACE2 Q9BYF1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15385544 0.86 SMN1; SMN2 (0.44) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1
SCHEMBL802601 0.83 ALDH1A1 (0.49) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1
SCHEMBL771198 0.83 HSD11B1 (0.48) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1
SCHEMBL770424 0.82 KDM1A (0.49) NPC1RAB9ASMN1; SMN2TACR1HSD11B1
SCHEMBL770367 0.81 NPC1 (0.46) NPC1RAB9ASMN1; SMN2TACR1HSD11B1
SCHEMBL771523 0.80 NPC1 (0.62) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1
SCHEMBL769577 0.78 SMN1; SMN2 (0.38) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1
SCHEMBL771146 0.76 NPC1 (0.48) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1
SCHEMBL772523 0.75 PRCP (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL771118 0.75 PRCP (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885RAB9A 2187/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885RAB9A 2217/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.